Last week, we introduced six of the companies presenting at the Health Accelerator Summit on September 21st before the Banff Venture Forum. This week, we’re sharing the next six companies representing MedTech and Devices, Pharma and Biotech, and Health IT sectors. Don’t forget to register for the summit to meet the representatives in person!
As a developer of precision medicine solutions for cancer, Pacylex’s proprietary paired biomarker and therapeutic technologies hold promise for a wide range of cancers.
Tealbook is a next-generation supplier knowledge platform, and helps companies instantly access and share trusted supplier intelligence to significantly reduce time and effort of supplier discovery, exponentially increasing the scale and productivity of procurement teams.
Tevosol is a medical device company developing the Ex-Vivo Organ Support System (EVOSS™), capable of increasing the number of donated organs viable for transplantation. The portable warm perfusion device is intended to achieve better recovery of organs, better resuscitation of dysfunctional organs, and longer preservation of function with the opportunity for ex-vivo treatment and evaluation.
Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to recognize, attack and kill cancers. The company is developing products that target leukemias, lymphomas and solid tumors and are just 18 months from human testing.
Vivametrica uses data from digital biomarkers (step counters, heart rate monitors, sleep trackers, etc.) and turns these basic measures into health analytics information, in the form of personal health scores. With this information the company created ways to predict risk for chronic diseases, and can also compare personal scores to those of others.
XORTX Pharma Corp. is a therapeutics company with a de-risked, fast track strategy to develop the first inhibitor of progressive kidney disease in diabetic nephropathy (DN) and polycystic kidney disease (PKD). XORTX aggregated and built a solid patent portfolio focused on the inhibition of a new mechanism of disease action that accelerates kidney disease.
The Health Accelerator Summit will also include a panel discussion with industry leaders from the health sector, and will explore strategies behind building a solid, innovative healthcare ecosystem.